Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

13.02.2023 - Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated to Evade the Formerly EUA-Approved Monoclonal Antibody Therapies and Preventatives ... Seite 1

Related Keywords

Ilya Trakht ,Seth Lederman ,Tonix Pharmaceuticals ,Treatment Guidelines Panel ,National Institutes Of Health ,Tonix Pharmaceuticals Holding Corp ,Drug Administration ,Columbia University ,Nasdaq ,Pharmaceuticals Holding ,Chief Executive Officer ,Guidelines Panel ,Associate Research Scientist ,Columbia University Vagelos College ,